Anthony Scarsella

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

David Wyles, Peter Ruane, Mark Sulkowski et al. · New England Journal of Medicine · 2015 · 422 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +17

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2019 · 96 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

Onyema Ogbuagu, Peter Ruane, Daniel Podzamczer et al. · The Lancet HIV · 2021 · 91 citations · Full text

Public Health, Pharmacology, Pharmacotherapy +17

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults

François Raffi, Chloe Orkin, Amanda Clarke et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2017 · 85 citations · Full text

Pharmacy, Pharmacotherapy, Clinical Pharmacology +16

Thymidine Analog and Multinucleoside Resistance Mutations Are Associated with Decreased Phenotypic Susceptibility to Stavudine in HIV Type 1 Isolated from Zidovudine-Naive Patients Experiencing Viremia on Stavudine-Containing Regimens

Lisa Ross, Anthony Scarsella, Stephen R. Raffanti et al. · AIDS Research and Human Retroviruses · 2001 · 34 citations

Life Sciences, Infectious Diseases, Pharmacology +17